Hormon Tedavisi Başarısız Olan Metastatik Prostat Kanserinde Provenge® (Sipuleucel-T) ile Aktif Hücresel İmmünoterapi Tedavisi

Sade dilde özet

Bu çalışma, hormon tedavisine rağmen ilerleyen metastatik prostat kanseri (prostate cancer) olan hastalarda Provenge® (Sipuleucel-T) adlı hücresel immünoterapiyi incelemiştir. Çalışmaya, hormon tedavisine rağmen ilerlemiş, lenf düğümlerine veya kemiğe yayılmış prostat kanseri olan hastalar katılabilmiştir. Çalışma Faz 3 aşamasında yürütülmüş ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz 3 (Phase 3)

Durum

Tamamlandı

Sponsor

Dendreon

Müdahale

Sipuleucel-T, APC-Placebo

Başlangıç

01.07.2003

Tahmini bitiş

01.01.2009

Ülkeler

United States, Canada

İlgili genler

Merkezler

• Laguna Hills, United States
• Loma Linda, United States
• Los Angeles, United States
• Los Angeles, United States
• Palm Springs, United States
• Sacramento, United States
• San Diego, United States
• San Diego, United States
• San Francisco, United States
• Denver, United States
• New Britain, United States
• Newark, United States
• Washington D.C., United States
• Washington D.C., United States
• Miami, United States
• Miami, United States
• Ocoee, United States
• Port Saint Lucie, United States
• Atlanta, United States
• Chicago, United States
• Chicago, United States
• Maywood, United States
• Park Ridge, United States
• Indianapolis, United States
• Baltimore, United States
• Greenbelt, United States
• Boston, United States
• Burlington, United States
• Minneapolis, United States
• Rochester, United States
• Las Vegas, United States
• Hackensack, United States
• West Orange, United States
• Albany, United States
• Albany, United States
• East Setauket, United States
• Hawthorne, United States
• New York, United States
• New York, United States
• New York, United States

+31

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

To qualify for this trial, you must have ALL of the following:

* Histologically documented adenocarcinoma of the prostate
* Cancer that has progressed while on adequate hormone therapy. This state of the disease is androgen independent prostate cancer (AIPC).
* Cancer that has spread outside the prostate (metastatic) to lymph nodes or bone. Please note that if your cancer has spread to organs (e.g., liver, lung, brain), you are not eligible for the study.
* The absence of or minimal current cancer-related pain

Please note that there are additional eligibility criteria. The study center will determine if you meet all of the criteria.

Study personnel will explain the trial in detail and answer any questions you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, study personnel will explain the reasons.